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ABSTRACT
The central importance of the serine/threonine protein kinase
mTOR (mammalian Target of Rapamycin) in the control of cell
growth and proliferation is well established. However, our
knowledge both of the upstream pathways controlling mTOR
activity and of the downstream events mediating these effects
is still seriously incomplete. We report a previously unsus-
pected role for the nonprotein-coding RNA GAS5 in the inhibi-
tion of T-cell proliferation produced by mTOR antagonists such
as rapamycin. GAS5 transcripts are up-regulated during growth
arrest and after rapamycin treatment, and GAS5 has recently
been shown to be necessary and sufficient for normal T-cell
growth arrest. Down-regulation of GAS5 using RNA interfer-
ence protects both leukemic and primary human T cells from
the inhibition of proliferation produced by mTOR antagonists.
The GAS5 transcript is a member of the 5 terminal oligopyri-
midine class of RNAs, which is specifically controlled at the
level of translation by the mTOR pathway, and the effects of
GAS5 on the cell cycle provide a novel and important link to the
control of proliferation. These observations point to a significant
advance in our understanding of the mechanism of action of
mTOR inhibitors, which is likely to lead to improvements in
immunosuppressive and cancer therapy.
The serine/threonine protein kinase mTOR occupies a key
position in the intracellular pathways that control mamma-
lian cell growth (Hay and Sonenburg, 2004; Wullschleger et
al., 2006). Extracellular signals, such as those provided by
growth factors and mitogens, and intracellular signals, such
as those determined by amino acid concentrations and ATP
levels, converge to regulate the state of activation of mTOR
(e.g., through dissociation from the endogenous inhibitor
FKBP38) (Bai et al., 2007). Subsequently, mTOR regulates
both cellular protein synthesis and cell proliferation (Fingar
et al., 2004; Hay and Sonenburg, 2004). The state of activa-
tion of mTOR is also important in the regulation of autoph-
agy and apoptosis in many mammalian cells, and all these
effects show significant variations among different cell types
(e.g., Decker et al., 2003; Chiang and Abraham, 2007).
mTOR, the mammalian homolog of the yeast protein ki-
nase Target of Rapamycin (Sehgal et al., 1975), was identi-
fied independently by five groups 15 years ago (for review,
see Abraham and Wiederrecht, 1996). Rapamycin binds in-
tracellularly to the immunophilin FKBP12; in turn, this com-
plex binds to mTOR, inhibiting mTOR activity and producing
the subsequent effects on cell behavior (Abraham and Wied-
errecht, 1996).
Rapamycin (Sirolimus) itself, a lipophilic macrolide iso-
lated from Streptomyces hygroscopicus, displays antifungal
activity associated with its interaction with fungal TOR ki-
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nases (Sehgal et al., 1975). Rapamycin also has potent anti-
proliferative effects on mammalian cells, which accounts for
its use as an immunosuppressant (Abraham and Wiederre-
cht, 1996) and, increasingly, in the therapy of leukemias and
other cancers (Abdel-Karim and Giles, 2008; Jiang and Liu,
2008). The specific inhibition of mTOR by rapamycin has
enabled many investigators to use it as a powerful pharma-
cological probe in ongoing investigations aimed at elucidat-
ing the critical intracellular signaling pathways upstream
and downstream of mTOR (Abraham and Wiederrecht, 1996;
Hay and Sonenburg, 2004; Wullschleger et al., 2006).
In mammalian lymphocytes, the antiproliferative effects of
rapamycin depend on the regulation of more than one signal-
ing pathway. Inhibition of mTOR results in inhibition of
protein synthesis, in part through reduced phosphorylation
of 4E-BP1 (e.g., Brunn et al., 1997; Fingar et al., 2004) and S6
kinase1 (Fingar et al., 2004; Tee and Blenis, 2005). In addi-
tion, inhibition of mTOR disproportionately reduces the
translation of several groups of RNAs, including 5TOP tran-
scripts (RNA species containing a 5 terminal oligopyrimi-
dine sequence; for review, see Meyuhas, 2000) and mRNAs
encoding several key cell-cycle regulators that have highly
structured 5 untranslated regions (Rosenwald et al., 1993).
The 5 oligopyrimidine tract of 5TOP RNAs is found mainly
on mRNAs encoding ribosomal and other proteins closely
involved with translation, so that mTOR inhibition preferen-
tially inhibits protein synthesis by blocking the production of
the protein synthesis machinery itself (Meyuhas, 2000). In-
hibition of passage through the cell cycle by inhibition of
mTOR has been suggested to result from several effects, first
from reduced translation of key cell cycle regulators, includ-
ing Myc (e.g., Zimmer et al., 2000) and second through effects
on signaling pathways controlling crucial cell-cycle regula-
tors such as p21Kip1 (Nourse et al., 1994) and p53 (Feng et al.,
2005.). Therefore, in this second category, inhibition of
mTOR acts by mechanisms that are potentially independent
of the effects on translation (Soulard and Hall, 2007; Hong et
al., 2008).
GAS5 is a 5TOP RNA; consequently, its translation is
controlled by the mTOR pathway. GAS5 encodes snoRNAs
(small nucleolar RNAs) in its introns, and its exons contain
a small open reading frame that does not appear to encode
a functional protein (Muller et al., 1998; Raho et al., 2000).
However GAS5 mRNA may still have functional effects
through interactions with steroid receptors that inhibit
their action (Kino et al., 2010). Several other mammalian
snoRNAs are encoded within the introns of genes coding
for nonfunctional proteins (e.g., Tycowski et al., 1996; Pel-
czar and Filipowicz, 1998). Because GAS5 transcript levels
increase on growth arrest and after rapamycin treatment
(Smith and Steitz, 1998), and GAS5 is both necessary and
sufficient for normal growth arrest in human T cells
(Mourtada-Maarabouni et al., 2008), we set out to test the
working hypothesis that the inhibition of T-cell prolifera-
tion produced by mTOR inhibition is mediated in part
through GAS5.
Materials and Methods
Materials. Rapamycin was purchased from Calbiochem (San Di-
ego, CA). Temsirolimus and everolimus were purchased from LC
Laboratories (Woburn, MA). Cyclosporine A was purchased from
Sigma (St. Louis, MO).
Cell Culture. The human T-leukemic cell lines CEM-C7 CMK1
(Norman and Thompson 1977; Williams et al., 1998) and MOLT-4
(Minowada et al., 1972) were maintained in RPMI 1640 medium
(Sigma) supplemented with 10% heat-inactivated fetal calf serum
(HyClone Laboratories, Logan, UT), 2 mM L-glutamine, and 200
g/ml gentamicin (Sigma), at 37°C in a 5% CO2 humidified incuba-
tor. All experiments were carried out using cells in logarithmic
growth phase.
Primary Lymphocyte Isolation and Culture. Whole blood
from healthy volunteers was collected into tubes containing 4%
sodium citrate (1:9 ratio). Each experiment was carried out on a
different donor. An equal volume of phosphate-buffered saline
(PBS) was added to the blood. The blood was pipetted carefully
over the Lymphoprep (2:1 volume; Axis-Shield UK, Kimbolton,
Cambridgeshire, UK) and centrifuged at 800g for 25 min at room
temperature. The mononuclear cells that accumulated at the in-
terface between the plasma and the Lymphoprep were then re-
suspended in ice-cold PBS and recovered after centrifugation
(1500g, 30 min). Cells were resuspended in complete RPMI me-
dium supplemented with 2.5 g/ml phytohemagglutinin (PHA;
Sigma) and incubated at 37°C in a 5% CO2 humidified incubator.
After 24 h, the nonadherent cells (depleted of macrophages) were
harvested, resuspended at a density of 106 cells/ml in complete
RPMI medium containing 2.5 g/ml PHA, and incubated for 3 to 4
days at 37°C before being used for the experiments.
Determination of Viable Cell Number. Viable cell number was
determined by nigrosin exclusion analysis and the LIVE/DEAD cell
viability assay (Invitrogen, Carlsbad, CA). In 96-well plates, 200 l
of cells (2  105 cells/ml) were incubated either without or with
rapamycin (2.5 M), temsirolimus (5 nM), or everolimus (10 nM) for
48 h. An aliquot of the control or treated cells was added to the
combined LIVE/DEAD assay reagents (as instructed by the manu-
facturer). Cells were then incubated for 40 min at room temperature.
Live cells stained with the green fluorescent dye and dead cells
stained with the red fluorescent dye were visualized and counted
using a Nikon Eclipse E400 fluorescence microscope.
DNA Synthesis Assay (BrdU Incorporation). Proliferation
was assessed by 5-bromo 2-deoxyuridine (BrdU) incorporation dur-
ing DNA synthesis using a colorimetric ELISA Kit (Roche Diagnos-
tics, Mannheim, Germany) (Zhang et al., 2009; Gharagozloo and
Amirghofran; 2007) according to the manufacturer’s instructions. In
brief, 200 l of cells (2  105 cells/ml) were cultured in flat-bottomed
96-well plates for 48 h in the presence or the absence of rapamycin or
mTOR inhibitors. Subsequent to labeling with 10 M BrdU (for the
final 18 h of the incubation period), DNA was denatured and cells
were incubated with anti-BrdU monoclonal antibody before the ad-
dition of substrate. The absorbance of the samples was measured
using a microplate reader (Wallac 1420 Victor Plate Reader;
PerkinElmer Life and Analytical Sciences, Waltham, MA) at 450 nm
with the absorbance at 690 nm as reference.
RNA Interference. Transfection of GAS5 and control small in-
terfering RNAs (siRNAs) was as described previously (Mourtada-
Maarabouni et al., 2008). Three different GAS5 siRNAs (reference
sequence AF141346) were designed by Ambion (Austin, TX) . Nega-
tive control siRNA was purchased from Ambion. All siRNAs were
purified by high-performance liquid chromatography, annealed, and
ready to use. Down-regulation of 65 to 80% in all the different cell
types and for all three GAS5 siRNAs was confirmed by quantitative
reverse transcriptase polymerase chain reaction (Supplemental Ta-
bles T1–T5).
Ki-67 Labeling. Expression of the Ki-67 protein is associated
with cell proliferation (Scholzen and Gerdes, 2000). Cells (106) were
suspended in 70% ethanol/30% PBS while vortexing. They were then
incubated at 20°C for 2 h. Fixed cells were then washed twice with
staining buffer (PBS with 1% fetal calf serum and 0.09% NaN3),
centrifuged for 10 min at 200g, and resuspended in 100 l in the
20 Mourtada-Maarabouni et al.
staining buffer. Anti-Ki-67 antibody (Santa Cruz Biotechnology,
Santa Cruz, CA) was added at 1:50 dilution. Cells were incubated for
30 min in the dark. Cells were washed twice with the staining buffer,
centrifuged at 200g for 10 min, and resuspended in 100 l of staining
buffer; the secondary antibody (anti-mouse IgG-fluorescein isothio-
cyanate; Santa Cruz Biotechnology) was added at a dilution of 1:200.
Cells were incubated in the dark for 1 h before being washed twice in
staining buffer. After centrifugation, the cells were resuspended in
50 l of staining buffer, and Ki-67-positive cells were detected using
a fluorescence microscope.
Preparation of Cells for Cell Cycle Analysis. Preparation of
cells and nuclear propidium iodide (PI) staining procedure for cell-
cycle analysis were performed according to standard procedures
(White et al., 1990; Kastan et al., 1991). Cells (106) were suspended
in 200 l of PBS, and fixed in 2 ml of ice-cold 70% ethanol/30% PBS.
After 30-min incubation on ice, the cells were centrifuged for 5 min
at 2000 rpm, and the supernatant was aspirated. Cells were resus-
pended in 970 l of PBS and 3 l of DNase-free RNase (Sigma) with
40 l of PI (1 mg/ml) and incubated for 30 min at 37°C before
analysis using the MoFlo flow cytometer Dako UK Ltd. (Ely, Cam-
bridgeshire, UK).
Statistical Analysis. Data are presented as the mean  S.E.
Statistical significance was determined by analysis of variance using
Origin 6.1 (OriginLab Corp, Northampton, MA). A p value of 0.01
was considered statistically significant.
Results and Discussion
GAS5 Down-Regulation Protects Leukemic T Cells
from mTOR Antagonists. The initial experimental mod-
els we employed to investigate the involvement of GAS5
were the rapamycin-sensitive human cell lines MOLT4
(Minowada et al., 1972) and CEM-C7 CKM1 (Norman and
Thompson, 1977; Williams et al., 1998). These leukemic T
cells proliferate continuously in culture without stimula-
tion, and this proliferation is inhibited by rapamycin (as
described for other T cells by several groups, e.g., Dumont
Fig. 1. GAS5-specific siRNAs protect against the inhibition of cell proliferation induced by 2.5 M rapamycin in MOLT-4 and CEM-C7 human T cell
lines. MOLT-4 and CEM-C7 T cells were transfected with specific GAS5 siRNAs or negative control siRNA [()siRNA] and cultured at 37°C. After
48 h, cells were exposed to rapamycin. MOLT-4 (A) and CEM-C7 (B) viable cell numbers were determined after 48 h by vital dye staining and the
LIVE/DEAD assay (see Materials and Methods). Results are calculated as the percentage of viable cell numbers relative to controls incubated in the
absence of rapamycin (mean  S.E.M. from five independent experiments). MOLT-4 (C) and CEM-C7 (D) cell proliferation was measured using
the BrdU colorimetric ELISA assay. Results are represented as the percentage inhibition of cell proliferation compared with control in the absence
of rapamycin. (mean S.E.M. from five independent experiments). , P 0.01 compared with ()siRNA. The original data are given as Supplemental
Fig. S1.
mTOR Antagonists Act through GAS5 21
Fig. 2. siRNAs targeting GAS5 protect the proliferation of MOLT-4 and CEM-C7 T cells from the inhibitory effects of mTOR inhibitors. Forty-eight
hours after transfection, siRNA-transfected cells were incubated with temsirolimus (5 nM) or everolimus (10 nM) for 48 h. Viable cell numbers for
MOLT-4 (A) and CEM-C7 (B) were determined by vital-dye staining and LIVE/DEAD assay. Results are calculated as the percentage of viable cell
numbers relative to controls incubated in the absence of inhibitors (mean  S.E.M. from five independent experiments). MOLT-4 (C) and CEM-C7 (D)
cell proliferation was assessed using the BrdU colorimetric ELISA assay. Results are represented as the percentage inhibition of cell proliferation
compared with controls in the absence of rapamycin. (mean  S.E.M. from five independent experiments). E and F, percentage of cells stained by
anti-Ki67 antibody. Data are represented as percentage inhibition of cell proliferation and represent means  S.E.M. from five independent
experiments. , P  0.01 compared with ()siRNA. Original data are provided in Supplemental Fig. S2.
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et al., 1990; Powell et al., 1999), as determined by counting
viable cells and by incorporation of bromodeoxyuridine.
The reduction in accumulated viable cell number of cell
populations treated with rapamycin for 48 h was substan-
tially alleviated by down-regulating GAS5 using any one of
three different siRNAs (Fig. 1, A and B). The inhibition of
T-cell DNA synthesis induced by rapamycin treatment, as
measured by the incorporation of BrdU, was also clearly
alleviated by all three GAS5 siRNAs (Fig. 1, C and D).
Although the exact alleviation of inhibition produced and
the relative order of effectiveness of the different GAS5
siRNAs showed some differences when different parame-
ters were monitored, the effects produced approached or
exceeded 50% in all cases. Such siRNA-mediated down-
regulation of GAS5 has no effect on untreated T cells over
the 48-h period examined (Mourtada-Maarabouni et al.,
2008).
These observations strongly suggested that a substantial
proportion of the effect produced by inhibition of mTOR on
these leukemic T-cell lines is mediated through GAS5. How-
ever, although there is strong evidence that the effects of
rapamycin are indeed due to inhibition of mTOR (Abraham
and Wiederrecht, 1996), it is always useful with pharmaco-
logical agents to examine the effects of other inhibitors to
exclude other potential mechanisms of action. The effects of
two other mTOR inhibitors, temsirolimus (Ma and Jimeno,
2007) and everolimus (Majewski et al., 2003), on the T-cell
lines were therefore examined. The effects of both these
mTOR inhibitors on MOLT4 and CEM-C7 proliferation (as
measured by monitoring viable cell numbers, by bromode-
oxyuridine incorporation, and by Ki-67 staining) were af-
fected by GAS5 down-regulation in a manner very similar to
the effects of rapamycin; at least 50% of the effects produced
by these reagents was abolished by each of the GAS5 siRNAs
(Fig. 2). These experiments with the three different mTOR
inhibitors and three different GAS5 siRNAs are therefore in
agreement, indicating that a substantial part of the reduc-
tion in MOLT4 and CEM-C7 cell proliferation induced by
mTOR inhibition is mediated through GAS5. These effects
are not seen for the calcineurin inhibitor cyclosporine (Sup-
plemental Fig. S4).
Analysis of the cell cycle by propidium iodide staining and
fluorescence-activated cell sorting revealed that the accumu-
lation of cells in G1 caused by rapamycin treatment was
clearly inhibited by GAS5 down-regulation in both MOLT4
and CEM-C7 T-cell lines (Fig. 3). The corresponding reduc-
tions in the proportions of cells in S and G2/M phases were
also inhibited. Rapamycin also caused a small increase in the
proportion of cells with sub-G1 DNA content (i.e., cells un-
Fig. 3. GAS5-specific siRNAs protect
MOLT-4 and CEM-C7 T cells from cell
cycle perturbations caused by rapamycin.
A, MOLT-4; B, CEM-C7.
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dergoing apoptosis). This increase as well was inhibited by
down-regulation of GAS5 (Fig. 3).
GAS5 Down-Regulation Protects Untransformed T
Cells from mTOR Antagonists. It is clearly important to
examine the role of GAS5 in untransformed cells, because all
of the above observations were made with transformed leu-
kemic T cells, which may not accurately reflect the physio-
logical situation. Primary cultures of human peripheral blood
leukocytes were therefore monitored after stimulation with
the mitogen PHA, which selectively stimulates the prolifer-
ation of T cells (Greaves and Bauminger, 1972), as described
previously (Mourtada-Maarabouni et al., 2008). Rapamycin
produced a clear reduction in proliferation over 24 h of incu-
bation, and this effect was substantially reduced by each of
the GAS5 siRNAs (Fig. 4, A and B). The rapamycin-induced
accumulation of T cells in G1 and the increase in cells with
sub-G1 DNA were again inhibited by down-regulation of
GAS5 (Fig. 4C). Although all three GAS5 siRNAs again alle-
viated the effects of rapamycin, there were noticeable differ-
ences in the response profiles, possibly because of the expres-
sion of different GAS5 splice variants in transformed versus
untransformed T cells.
It was important to test the effect of GAS5 down-regulation
on the action of temsirolimus and everolimus on these nor-
mal human T cells. Once again, the reduction in T-cell pro-
liferation produced by the two mTOR inhibitors was reduced
by at least 50% by each of the GAS5 siRNAs (Fig. 4, D–F).
The consistent observations made in the above experi-
ments, using both T-cell lines and untransformed T cells,
with three mTOR inhibitors and three GAS5 siRNAs,
strongly suggest that a substantial proportion of the effects of
mTOR inhibition on these cells involves GAS5. This conclu-
sion is entirely consistent with the established effect of
mTOR in regulating GAS5 transcript levels (Smith and Ste-
itz, 1998) together with the recently established critical role
of GAS5 in the regulation of T-cell growth arrest (Mourtada-
Maarabouni et al., 2008).
When mTOR is active (i.e., when conditions are condu-
cive to cell growth), 5TOP RNAs are actively translated
(for review, see Meyuhas, 2000). For most of these RNAs,
this results in the synthesis of proteins required for in-
creased protein synthesis. However, in the case of GAS5,
the active translation of the short open reading frame in
exon 3, which is normally followed by several further ex-
ons, results in the rapid degradation of the GAS5 tran-
script, most likely by nonsense-mediated decay (Smith and
Steitz, 1998; Isken and Maquat, 2007). When mTOR activ-
ity is reduced (e.g., by the pharmacological agents used
Fig. 3. Continued. B, T cells were trans-
fected with specific GAS5 siRNAs or neg-
ative control siRNA [()siRNA] and cul-
tured at 37°C. After 48 h, cells were
exposed to 2.5 M rapamycin. Cell-cycle
analysis was carried out after a further
24 h. DNA content was quantified by pro-
pidium iodide staining of fixed cells and
fluorescence flow cytometry. Results are
represented as the means  S.E.M. (n 
5). , P  0.01 compared with control in
the absence of rapamycin. Representative
histograms are also shown, and full re-
sults for all three GAS3 siRNAS are given
in Supplemental Tables T6 and T7.
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Fig. 4. Changes in GAS5 expression modulate the response of human peripheral blood lymphocytes to mTOR inhibitors. Peripheral blood lymphocytes from a
single healthy volunteer were stimulated with 2.5 g/ml PHA and transfected with siRNAs targetingGAS5 or with negative control ()siRNA. Forty-eight hours
after transfection, siRNA-transfected cells were incubated with either rapamycin 2.5 M (A–C) or 5 nM temsirolimus or 10 nM everolimus (D–F) for 48 h.
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here), translation is inhibited, and nonsense-mediated de-
cay, which depends on active translation (Isken and Ma-
quat, 2007), no longer occurs. GAS5 transcript levels
therefore increase (Smith and Steitz, 1998). Because up-
regulation of GAS5 results in T-cell growth arrest (Mour-
tada-Maarabouni et al., 2008), cell proliferation and via-
bility would be expected to decrease in these cell cultures,
and this prediction is amply confirmed by the experimental
observations presented here. GAS5 mRNA has recently
been shown to produce effects on epithelial cell growth and
survival by antagonizing the action of steroid hormones
(Kino et al., 2010) through competing with steroid re-
sponse elements in DNA for steroid hormone/receptor com-
plexes. Although these effects may account in part for
some of our observations, the best known effects of glu-
cocorticoid hormones on T cells are proapoptotic rather
than antiapoptotic (e.g., Ashwell et al., 2000). Indeed, we
have already shown that the well established proapoptotic
effects of glucocorticoids on T cells are alleviated by down-
regulation of GAS5 (Mourtada-Maarabouni et al., 2008),
indicating that GAS5 carries out its effects by mechanisms
other than by antagonizing the glucocorticoid receptor in
these circumstances.
Although our observations show that GAS5 plays a ma-
jor role, the effects of GAS5 siRNAs are incomplete. Be-
cause siRNA transfection efficiency is itself below 100%
(65–85%; see Supplemental Tables T1–T5), this probably
accounts for much but not all of the incompleteness of
these effects. The observation that GAS5 down-regulation
does not entirely alleviate the effects of mTOR inhibitors,
however, is consistent with previous reports, which indi-
cate that the regulation of cell cycle control points, such as
the down-regulation of p27Kip1 (Nourse et al., 1994; Hong
et al., 2008) and the inhibition of translation of critical cell
cycle regulators (e.g., Rosenwald et al., 1993), can play
important roles in the effects of mTOR inhibitors. Given
the significant cell-type dependence of the effects of mTOR
inhibitors (e.g., Decker et al., 2003; Chiang and Abraham,
2007), it is likely that the relative contributions of GAS5
and the other factors vary among different cell types.
GAS5 was originally identified from a subtraction cDNA
library enriched for sequences overexpressed at growth
arrest (Schneider et al., 1988), and its level of expression
Fig. 4. Continued. A and D, viable cell numbers were determined by
vital-dye staining and LIVE/DEAD assay. Results are represented as the
percentage viable cell number relative to controls incubated in the ab-
sence of mTOR inhibitors (mean  S.E.M. from six independent experi-
ments), Changes in GAS5 expression modulate the response of human
peripheral blood lymphocytes to mTOR inhibitors. Peripheral blood
lymphocytes from a single healthy volunteer were stimulated with 2.5
g/ml PHA and transfected with siRNAs targetingGAS5 or with negative
control ()siRNA. Forty-eight hours after transfection, siRNA-trans-
fected cells were incubated with either rapamycin 2.5 M (A–C) or 5 nM
temsirolimus or 10 nM everolimus (D–F) for 48 h. A and D, viable cell
numbers were determined by vital-dye staining and LIVE/DEAD assay.
Results are represented as the percentage viable cell number relative to
controls incubated in the absence of mTOR inhibitors (mean  S.E.M.
from six independent experiments), C, DNA content of transfected lym-
phocytes 24 h after exposure to rapamycin was monitored by PI staining
and flow cytometry. The results obtained from one of the GAS5 siRNAs
are presented (full results for all three GAS5 siRNAs are given in Sup-
plemental Table T8). Data represent the mean  S.E.M. from four inde-
pendent experiments, each carried out with cells from a different donor).
B and E, cell proliferation was measured using the BrdU colorimetric
ELISA assay. F, percentage inhibition of proliferation as monitored by
staining by anti-Ki67 antibody. Results are represented as inhibition of
cell proliferation compared with controls in the absence of mTOR inhib-
itors (mean  S.E.M. from six independent experiments). , P  0.01
compared with controls.
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has been shown to increase in several situations in which
cell growth is inhibited [e.g., in saturation density-
arrested cells (Coccia et al., 1992) and under conditions of
amino acid insufficiency (Fleming et al., 1998)]. The func-
tional importance of GAS5 was first indicated by its isola-
tion by functional expression cloning as a gene regulating
T-cell survival (Williams et al., 2006) and was confirmed
by the demonstration that GAS5 is both necessary and
sufficient for normal growth arrest in both normal and
leukemic human T cells (Mourtada-Maarabouni et al.,
2008).
Regulation of GAS5 transcript levels by mTOR therefore
provides a clear link between the control of translation and
the control of cell division and survival. Because other
5TOP RNAs encode proteins required for translation
(Meyuhas, 2000), it may be that the GAS5 open reading
frame also encoded such a functional protein at some time
in its evolutionary history. This open reading frame sub-
sequently would become redundant through gene duplica-
tion and would be down-regulated during active cell
growth through nonsense-mediated decay after the ap-
pearance of a stop codon in an early exon (Isken and
Maquat, 2007). The subsequent acquisition of growth- and
survival-suppressing properties by GAS5 transcripts, po-
tentially mediated in part by the inhibition of steroid hor-
mone action by GAS5 RNA reported recently (Kino et al.,
2010), therefore allowed inhibition of translation to be
linked both to inhibition of cell cycle progression and to
induction of cell death (Mourtada-Maarabouni et al.,
2008).
The importance of GAS5 and related genes in the control
of the proliferation and survival of normal cells had not
been anticipated before its identification by functional
cloning (Williams et al., 2006; Mourtada-Maarabouni et
al., 2008), illustrating the power of such forward genetics
strategies (Stark and Gudkov, 1999; Williams and Farza-
neh, 2004). The demonstration of the key role played by
GAS5 in the mTOR pathway represents an unexpected
twist in the control of mammalian cell proliferation and
survival. It is likely that this advance will lead to further
improvements in the therapy of diseases involving the
mTOR pathway, particularly leukemia, other cancers, and
autoimmune disease.
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